Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 5/20 | 0.67 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.60 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.52 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.52 |
| ▸ | JUN | P05412 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.49 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.49 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6036142 | 0.88 | HDAC8 (0.65) | HDAC8LTB4RLTB4R2JUNNFKB1 | |
| SCHEMBL6036139 | 0.88 | HDAC8 (0.65) | HDAC8LTB4RLTB4R2JUNNFKB1 | |
| SCHEMBL7272006 | 0.79 | CDK4 (0.68) | HDAC8PTGER4PTGER2KDM4EPTGER1 | |
| SCHEMBL7272001 | 0.79 | CDK4 (0.68) | HDAC8PTGER4PTGER2KDM4EPTGER1 | |
| SCHEMBL344657 | 0.79 | PTGER3 (0.68) | HDAC8LTB4RLTB4R2PTGER4PTGER2 | |
| SCHEMBL344658 | 0.79 | PTGER3 (0.68) | HDAC8LTB4RLTB4R2PTGER4PTGER2 | |
| SCHEMBL2573994 | 0.79 | TUBB1 (0.57) | HDAC8KDM4EALDH1A1 | |
| SCHEMBL6035013 | 0.78 | HDAC8 (0.80) | HDAC8PTGER4PTGER2KDM4EALDH1A1 | |
| SCHEMBL6035015 | 0.78 | HDAC8 (0.80) | HDAC8PTGER4PTGER2KDM4EALDH1A1 | |
| SCHEMBL4031129 | 0.77 | KDM4E (0.65) | HDAC8LTB4RLTB4R2PTGER4PTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | APP 3925/4885HDAC8 1077/4885LTB4R 535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.